- Humanigen Inc (NASDAQ:HGEN) has been informed of preliminary topline results from the ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients.
- The trial did not achieve statistical significance on the primary endpoint, defined as the proportion of patients with baseline CRP<150 mg/L and age<85 years, alive and without mechanical ventilation through Day 29.
- The data also showed a non-significant trend toward a reduction in mortality in the overall patient population.
- There were no new safety signals attributed to lenzilumab in the ACTIV-5/BET-B study.
- “We are grateful for the constructive collaboration with NIH/NIAID; while the ACTIV-5/BET-B study showed signs of a clinical effect, the benefit demonstrated was not able to confirm the positive results we saw in our Phase 3 LIVE-AIR study,” said Cameron Durrant, Chairman and Chief Executive Officer, Humanigen.
- The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a National Institutes of Health (NIH) directed public-private partnership to develop a coordinated research strategy for prioritizing and speeding the development of the most promising treatments and vaccines.
- Price Action: HGEN shares are down 65.20% at $1.04 during the premarket session on the last check Wednesday.
JMP Securities Initiates Coverage On Exelixis with Market Outperform Rating, Announces Price Target of $26
JMP Securities analyst Silvan Tuerkcan initiates coverage on Exelixis (NASDAQ:EXEL) with a Market Outperform rating and announces Price Target of $26.
